Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Vanguard Short Term Corporate Bond ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Vanguard Short Term Corporate Bond ETF trades at $78.7. Which is the better fit depends on your goals.
| ALNY | VCSH | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Fixed Income |
52-Week High | $491.22 | $80.20 |
52-Week Low | $278.09 | $78.61 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
VCSH trades at $78.61, down 0.1% with a bearish technical outlook showing 16 sell signals versus 1 buy. The ETF maintains consistent dividend distributions with recent payments of $0.29-$0.30 per share. News coverage highlights VCSH's competitive expense ratio and yield advantages over comparable short-term bond ETFs, though institutional positions show mixed adjustments.
The short-term corporate bond ETF faces headwinds from the Fed's indication of no rate cuts in 2026, potentially limiting near-term upside. Current technical weakness suggests cautious positioning, though the neutral oscillator reading and institutional interest from firms like BlueSky Wealth Advisors provide some support. The primary risk remains interest rate sensitivity in the current monetary policy environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
